CIGB director, Marta Ayala, pointed out that the use of the product as a therapeutic alternative in head and neck squamous cell carcinoma is also being investigated.
Having Heberferon is an advantage for the quality of life of patients suffering from basal cell carcinoma, since approximately 90 percent of the lesions arise on the face and the first indicated therapeutic option is surgery, which can leave esthetic sequelae.
The drug, she pointed out, can be used against this malignant skin disease of any subtype, size and location, whether in a young person or an adult, without generating significant adverse effects.
So far, more than 4,000 patients from all over the country have benefited from its use, with favorable results in the control and improvement of this neoplasm, Ayala was quoted as saying by Granma newspaper.
If the results are as expected, the sanitary registration could be ready between the end of 2022 and the first half of 2023.
The newspaper recalls that Heberferon became part of the treatment protocol against the SARS-CoV-2 coronavirus, which causes Covid-19, and was administered to high-risk patients, pregnant women and children.
It was remarkably effective in making patients negative within a few days of the first dose and in boosting the anti-inflammatory response, a key element in reducing the number of patients in serious and critical condition.